MicroRNA-21 Identified as Predictor of Cancer Outcome: A Meta-Analysis

Wenjie Zhu, Binghe Xu*

Department of Medical Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Abstract

Background: Growing evidence from recent studies has revealed the association of microRNA-21 (mir-21) with outcomes in multiple cancers, but inconsistent findings have been reported, which rationalized a summary and analysis of available data to investigate the prognostic role of mir-21.

Materials and Methods: Eligible studies were identified through several search strategies and assessed for quality. Data was extracted from studies in terms of baseline characteristics and key statistics such as hazard ratio (HR), 95% confidence interval (CI) and P value, which were utilized to calculate pooled effect size.

Results: 25 studies were included in the meta-analysis to evaluate the prognostic role of mir-21 in malignant tumors. Elevated mir-21 level was demonstrated to moderately predict poor overall survival (OS) (HR = 1.903, 95% CI: 1.713–2.113, P = 0.000) and disease-free survival (DFS) (HR = 1.574, 95% CI: 1.139–2.175, P = 0.006) by the fixed and random effect model respectively. Importantly, subgroup analysis disclosed significant association between increased mir-21 level in cancerous tissue and worse survival status. Furthermore, over-expression of mir-21 was an independent prognostic factor for non-small cell lung cancer (NSCLC) and pancreatic cancer patients, with the pooled HR being 2.153 (95% CI: 1.693–2.739, P = 0.000) and 1.976 (95% CI: 1.639–2.384, P = 0.000).

Conclusions: Over-expression of mir-21, especially in cancerous tissue, was effectively predictive of worse prognosis in various carcinomas. Non-invasive circulating mir-21, however, exhibited modest ability to discriminate outcomes. Major concerns about mir-21 assay standardization and selection of specimen need to be fully addressed before its practical implementation in management of cancer.

Citation: Zhu W, Xu B (2014) MicroRNA-21 Identified as Predictor of Cancer Outcome: A Meta-Analysis. PLoS ONE 9(8): e103373. doi:10.1371/journal.pone.0103373

Editor: Domenico Coppola, H. Lee Moffitt Cancer Center & Research Institute, United States of America

Received February 25, 2014; Accepted June 29, 2014; Published August 6, 2014

Copyright: © 2014 Zhu, Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by National Natural Science Foundation grant [81372830], Beijing Hope Run Special Fund [LC2013L09] and Capital Clinical Feature Applied Research Fund [Z141107002514010]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* Email: bhxu@hotmail.com

Introduction

MicroRNAs (miRNAs) represent an evolutionarily conserved class of endogenous small non-coding RNA molecules that are approximately 18–25 nucleotides in length and post-transcriptionally modulate gene expression in a sequence-specific manner [1–3]. These tiny regulators mainly function via pairing with approximately 18–25 nucleotides in length and post-transcriptional profiling studies have identified miRNAs that are aberrantly expressed in a variety of human cancers, and their association with cancer has prompted the functional classification of miRNAs into oncogenic (oncomirs) and tumor suppressor miRNAs. Oncomirs generally inhibit the expression of tumor suppressor genes and/or genes that are involved in cell apoptosis and differentiation [10,11], among which mir-21 has been the most extensively explored one in human neoplasms of various origins.

Evidence about the pro-neoplastic role of mir-21 from fundamental and clinical studies is encouraging. When highly expressed, mir-21 was observed to promote cellular proliferation, survival, invasion and migration in multiple cancer cell lines [12–14]. Meanwhile, knock-down of mir-21 by anti-sense oligonucleotides caused notable decrease in cancer cell survival in vitro and tumor growth in vivo in a murine xenograft model, which was accompanied by ablated expression of anti-apoptotic protein Bcl-2 and enhanced apoptosis [15–20]. Ever since the first report about its over-expression in glioblastoma in 2005 [16], mir-21 has been found up-regulated in a wide range of malignancies [21–24], which indicated its diagnostic role of distinguishing cancer patients from healthy individuals. More importantly, recent studies investigating its association with cancer outcomes have disclosed the prognostic value of mir-21, with its high expression predicting worse survival status in malignancies including breast cancer, lung cancer, pancreatic cancer, colorectal cancer, and so on [25–31].
However, consensus has not been reached as to the reliability of mir-21 as a prognostic biomarker in cancer because of some opposite results [32–35]. Considering the weakness of an individual study, it’s necessary to perform a meta-analysis to address the inconsistence of literature by systematically summarizing available findings.

In the current study, we carried out a meta-analysis to assess the prognostic significance of mir-21 in cancer. Since inconsistent evidence existed about the association of mir-21 with pancreatic and NSCLC survival, we performed cancer-specific subgroup analyses to clarify the correlation of mir-21 with these two malignancies. As for colorectal cancer however, the vast majority of available studies demonstrated that mir-21 over-expression could predict poor survival in colorectal cancer, which made it less necessary to re-prove previous finding in our study. In addition, implications for future research and feasibility of application in clinical practice were also explored.

Materials and Methods

The meta-analysis was conducted following the guidelines of the Meta-analysis of Observational Studies in Epidemiology group (MOOSE) [36].

Search strategy and study selection
MEDLINE, EMBASE and the Cochrane library electronic databases were systematically searched to identify relevant studies published from 1966 to 19 December 2013 using the following three sets of key words and their combination: “microRNA 21”, “cancer OR carcinoma OR tumor OR neoplasm OR malignancy” and “prognosis OR survival OR mortality OR death OR relapse OR recurrence OR metastasis OR outcome”. The titles and abstracts of the publications were carefully reviewed. In addition, a manual search was performed using references from relevant literature to further identify eligible studies.

Eligible studies enrolled participants diagnosed with a certain type of solid tumor, which measured the expression of miR-21 in cancerous tissues or circulatory system and investigated the association between miR-21 expression level and survival status. Articles were excluded if they were non-English articles, review articles, letters, economic analyses, or laboratory studies. Other exclusion criteria included studies analyzing a set of miRNAs altogether, studies dividing patients according to non-dichotomous miR-21 expression levels and studies lacking key information such as hazard ratio (HR), 95% confidence interval (CI) and P value. When multiple publications about a study were identified, only those representing the latest reference and reporting the outcomes were included.

Quality assessment
Following a critical review checklist of the Dutch Cochrane Centre proposed by MOOSE, we systematically assessed the quality of all the studies included [36]. Major items to be evaluated are as follows: (i) clear description of study population and origin of country, (ii) clear description of disease type, (iii) clear description of study design, (iv) clear definition of cancer outcomes, (v) clear explanation of measurement of miR-21, (vi) clear definition of cutoff value of miR-21 level and (vii) sufficient duration of follow-up. If a study failed to specify information concerning any aspect stated above, it would be excluded so as not to compromise the quality of the meta-analysis.

Data extraction and conversion
Data was extracted from all eligible studies in duplicate by two independent reviewers. Disagreement was resolved by consulting with a third reviewer. Data was collected with regard to the following aspects: (i) publication details: the last name of first author, year of publication and study design; (ii) baseline characteristics of study population: country, sample size, site and staging of cancer; (iii) miR-21 assay specimen, method and cut-off value of mir-21 level and (iv) HR of increased miR-21 for overall survival (OS), relapse-free survival (RFS) or disease-free survival (DFS), as well as their 95% CI and P value. In most cases we directly derived HR and 95% CI from the original article, with an HR of >1 being associated with elevated risk of mortality or recurrence. If HR and 95% CI were absent, the total number of observed deaths or recurrences and the sample size in each group were extracted to calculate HR as previously described [37]. If only Kaplan-Meier curves were available, data was extracted from the survival plots and an estimated HR was then calculated as previously described [37].

Statistical analysis
Heterogeneity among included studies was evaluated using Cochran’s Q test and Higgins I-squared statistic. A random effect model (Der Simonian and Laird method) was adopted as the pooling method if substantial heterogeneity was observed (P < 0.05), while the fixed effect model was applied in the absence of between-study heterogeneity (P > 0.05). Publication bias was assessed using the funnel plot with the Egger’s bias indicator test [38]. Sensitivity analysis (influence analysis) was performed to test how robust the pooled effect size was to the removal of individual studies. An individual study was suspected to have excessive influence if the point estimate was outside the 95% CI of the combined effect size after it was removed from the analysis. Subgroup analysis was conducted based on the type of specimen collected and the site of cancer. All of the P values were two-sided, with P < 0.05 considered statistically significant. All analyses were performed using STATA version 12.0 (Stata, College Station, TX, USA).

Results

Literature screening and study characteristics
Figure 1 presented the process of literature screening and study selection. After preliminary on-line search, 594 original articles concerning mir-21 and cancer prognosis were retrieved out of EMBASE, MEDLINE and the Cochrane library databases. 548 papers were excluded from the present study after manual screening of titles, abstracts and key words because they were review articles, letters, laboratory studies, non-English contributions or irrelevant to the current analysis. Full texts of the remaining 46 articles were carefully reviewed and assessed, and 22 articles were further removed due to non-dichotomous classification of mir-21 expression levels or lack of key statistics such as HR, 95% CI and P value. Of the 29 candidate studies from 24 published papers, one study evaluated a series of miRNAs as a whole [39], 1 article failed to provide definite information about cancer staging [40], and 2 studies were considered ineligible due to compromised generalizability since the data was derived from cancer patients restricted to a certain stage [41,42]. Finally, 25 studies in all were included in the meta-analysis to evaluate the prognostic role of mir-21 in malignant tumors.

The main characteristics and basic information of eligible studies were summarized in Table S1. The studies enrolled 3,038 patients from the United States, the United Kingdom, Canada,
Italy, Norway, Greece, Denmark, China, Taiwan and Japan. All the studies were retrospective, which dealt with a wide range of carcinomas including breast cancer, colorectal cancer, lung cancer, pancreatic cancer, melanoma, glioma, gastric cancer, oral cancer, hepatocellular carcinoma, renal cell carcinoma and prostate cancer. The majority of the studies examined the expression of mir-21 in cancerous tissue, yet 6 studies targeted blood serum as a source of interest. Notably, in one study Ota and his colleagues sought to quantify the level of mir-21 in bone marrow obtained from breast cancer patients. In situ hybridization (ISH) was applied in two studies although quantitative real-time PCR (qRT-PCR) remained as the predominant way of mir-21 detection. 15 studies adopted the median fold change as the cut-off value of mir-21 expression, with 2-fold, 5-fold and mean fold change used in the other studies. 7 of the 25 studies explored the association of mir-21 with disease-free survival (DFS), relapse-free survival (RFS) or time to progression (TTP), and 18 focused on its relation with overall survival (OS) of cancer patients.

Mir-21 and overall survival

Figure 2A displayed the forest plot of the analysis about mir-21 and OS. 18 studies in all were subjected to analysis. The fixed effect model was utilized to calculate the pooled effect size due to absence of heterogeneity among the studies ($I^2 = 33.0\%$, $P = 0.087$). Mir-21 high expression was demonstrated to moderately predict poor OS regardless of the site of cancer ($HR = 1.903$, 95% CI: 1.713–2.113, $P = 0.000$). Afterwards we carried out subgroup analyses according to the types of sample collected for mir-21 assay, namely cancerous tissue and blood serum. For the 14 studies using frozen or fresh tissues, the fixed effect model the pooled HR for OS was 1.986 (95% CI: 1.760–2.241, $P = 0.000$), suggesting that over-expression of mir-21 in cancer tissues was predictive of worse outcome. As for the 4 studies targeting serum mir-21, it turned out that elevated mir-21 level in serum was associated with undesirable prognosis, with the combined HR for OS being 1.669 (95% CI: 1.351–2.062, $P = 0.000$).

Mir-21 and disease-free survival

Figure 2B showed the analysis results of 7 studies about DFS. Evident heterogeneity was detected among the seven studies ($I^2 = 66.1\%$, $P = 0.007$), which rationalized further exploration to disclose factors contributing to this heterogeneity. The combined HR was calculated to be 1.574 (95% CI: 1.139–2.175, $P = 0.006$) by the random model, providing hints that increased expression of mir-21 was correlated with reduced DFS of cancer patients.

Subgroup and sensitivity analysis of DFS studies

In order to specify the source of heterogeneity the DFS studies were stratified based on the types of specimen, yet prominent heterogeneity was again identified within both groups (2 studies in circulating mir-21 group $I^2 = 78.9\%$, $P = 0.029$; 5 studies in tissue mir-21 group $I^2 = 69.1\%$, $P = 0.012$).[Fig. 2B]. However, substan-
tial heterogeneity could also be attributed to the wide-ranging origins of study cohorts, so the studies were then entered into subgroup analysis by countries of the study population (Asian and non-Asian countries). To a huge extent heterogeneity was dissolved within three non-Asian studies ($I^2 = 0.0\%$, $P = 0.791$) rather than the four Asian studies ($I^2 = 78.5\%$, $P = 0.003$), and elevated mir-21 manifested itself as more indicative of shortened DFS in non-Asian cancer patients ($HR = 1.951$, 95% CI: 1.257–3.027, $P = 0.003$) than Asian cohorts ($HR = 1.445$, 95% CI: 0.952–2.193, $P = 0.084$).

After exclusion of the study by Jiang et al, heterogeneity among DFS studies was significantly diminished ($I^2 = 50.4\%$, $P = 0.073$). And the studies enrolled 305 participants from USA, the UK, Italy, China and Japan were put to analysis, which displayed great homogeneity ($I^2 = 0.0\%$, $P = 0.530$). Fixed effect model was applied and the pooled HR being 2.153 by fixed effect model (95% CI: 1.693–2.739, $P = 0.000$). When it came to pancreatic cancer, 8 studies involving 831 participants from USA, the UK, Italy, China and Japan were put to analysis, which displayed great homogeneity ($I^2 = 0.0\%$, $P = 0.530$). Fixed effect model was applied and the pooled HR was 1.976 (95% CI: 1.639–2.384, $P = 0.000$), revealing significant association between increased mir-21 level and worse pancreatic cancer survival status (Fig. 3B). Additionally, the studies on NSCLC and pancreatic cancer were further stratified by sample type, and it was discovered that both tumor and circulating mir-21 over-expression remained predictive of undesirable cancer outcome.

Cancer-specific analysis

Subsequently we set out to throw light upon the prognostic role of mir-21 in certain cancers. Figure 3A represented the forest plot of the analysis of non-small cell lung cancer (NSCLC) studies. Three studies enrolling 405 patients from USA, China, Japan and Norway went through analysis. Inter-study heterogeneity was absent ($I^2 = 0.0\%$, $P = 0.701$). Obviously over-expression of mir-21 was an independent prognostic factor for NSCLC patients, with the pooled HR being 2.153 by fixed effect model (95% CI: 1.693–2.739, $P = 0.000$). When it came to pancreatic cancer, 8 studies involving 831 participants from USA, the UK, Italy, China and Japan were put to analysis, which displayed great homogeneity ($I^2 = 0.0\%$, $P = 0.530$). Fixed effect model was applied and the pooled HR was 1.976 (95% CI: 1.639–2.384, $P = 0.000$), revealing significant association between increased mir-21 level and worse pancreatic cancer survival status (Fig. 3B). Additionally, the studies on NSCLC and pancreatic cancer were further stratified by sample type, and it was discovered that both tumor and circulating mir-21 over-expression remained predictive of undesirable cancer outcome.

Publication bias

Finally, publication bias of the included studies was assessed by funnel plot and Egger’s test, which was summarized in Figure 4. Figure 4D exposed the results of Egger’s test, which was used to provide statistical evidence of funnel plot symmetry. Publication bias was not detected in the overall analysis of 25 enrolled studies ($P = 0.055$). For the eighteen OS studies Egger’s test revealed no evidence of publication bias ($P = 0.150$) while with seven DFS studies publication bias existed ($P = 0.048$). Similar results were demonstrated in the funnel plot (Fig. 4A–C).

Discussion

In the current meta-analysis which pooled global high-quality studies concerning mir-21 and cancer prognosis, it was demonstrated that over-expression of mir-21, especially in cancerous tissues, was effectively predictive of poor survival in a variety of cancers, in terms of both OS and DFS. For NSCLC and pancreatic cancer, significant association was verified between elevated mir-21 level and worse long-term survival.

The studies setting OS as primary endpoint were largely homogeneous, which made it relatively safe to conclude that high level of tissue or circulating mir-21 was predictive of reduced OS.

Nevertheless caution should be taken when interpreting the analysis results of the DFS studies, which exhibited prominent heterogeneity. In the subgroup analysis by types of sample, mir-21 level in cancerous tissues ($HR = 1.725$, 95% CI: 1.073–2.773, $P = 0.024$) rather than blood serum ($HR = 1.403$, 95% CI: 0.769–2.538, $P = 0.269$) was associated with decreased DFS in multiple cancers. To sum it up, promoted mir-21 level in cancer tissues was related to greater risk of relapse and mortality while the predictive force of circulating mir-21 only applied to OS given the analysis of available studies.

Since the initial recognition of the association of mir-21 with cancer in 2005 [16], mir-21 has stood out as the most extensively explored miRNAs. Recent studies involving cancer cell lines and xenograft models have implicated the oncogenic role of mir-21. Accumulating evidence has supported mir-21 as a potential diagnostic and prognostic biomarker in various carcinomas. In our meta-analysis study, it was preliminarily concluded that mir-21 level facilitated the prediction of long-term survival in cancers including NSCLC and pancreatic cancer, which further validated the prognostic value of this oncomir. As a matter of fact, the noteworthy association between aberrant mir-21 expression and poor survival could be best illuminated by its indispensable role in carcinogenesis and metastatic cascade. Latest findings have shed light upon the underlying oncogenic mechanisms of mir-21, which
exerted profound influence over the basic hallmarks of cancer, including cell proliferation, apoptosis, differentiation, invasion and migration [8–11]. The mir-21 gene is located on chromosome 17q23.2 within the common fragile site FRA17B, which is frequently observed to be amplified in numerous malignancies [21]. Of great importance, the oncogenic effect of mir-21 could be primarily explained by its transcriptional targets and downstream signal pathways. So far, validated targets of mir-21 included programmed cell death 4 gene (PDCD4), tropomyosin 1 (TPM1), phosphatase and tensin homolog (PTEN), chromosome condensation protein G (NCAPG), reticulon 4 isoform A (RTN4) and other cancer-related genes [12–15,17,44–46]. Altogether, the vital cellular pathways regulating cell proliferation, apoptosis and cell cycle such as Ras [47], p53 [48], PI3K-Akt-mTOR pathway [49], as well as target genes compose an intricate network of mir-21 modulation.

As mounting evidence from retrospective studies indicated mir-21 as a promising tumor marker, a series of quantitative analyses were carried out based on published studies to help determine its diagnostic and prognostic value. A meta-analysis by Xia et al demonstrated that in colorectal cancer high-level mir-21 was moderately predictive of unfavorable overall survival [HR = 1.76, 95% CI: 1.34–2.32, \( P = 0.000 \)] [50]. On the basis of 17 studies, Fu et al reported in a systematic review and meta-analysis that mir-21 over-expression predicted worse overall and relapse-free survival in several cancers including head and neck squamous cell carcinoma (HNSCC) and digestive system cancers, with the pooled HR being 1.69 (95% CI: 1.33–2.16, \( P < 0.001 \)) for OS and 1.48 (95% CI: 1.03–2.11, \( P < 0.033 \)) for DFS [51]. Similar results were obtained by Wang et al in their meta-analysis about the prognostic significance of circulating mir-21 in human cancer, which included six studies and estimated the combined HR to be 2.37 (95% CI: 1.83–3.06, \( P = 0.000 \)) [52]. The data derived from studies stated above however, should be translated with caution due to dramatic across-study heterogeneity and small sample capacity, which justified further analysis to validate the prognostic role of mir-21. Compared to previous meta-analyses, the current one involved as many as 25 high-quality studies including numeral newly published ones, most of which focused on pancreatic cancer. As a matter of fact, opinions are divided as to the association of mir-21 expression with pancreatic cancer outcome and in latest years extensive translational research has cast light upon this dispute. In the present work, we conducted subgroup analysis of pancreatic cancer studies, which added convincing evidence that mir-21 over-expression predicted reduced survival regardless of its sample type. Notably, we set and implemented exacting inclusion and exclusion criteria to ensure the quality of involved studies and thus reliability of the pooled results. For instance, if a study dealt with a series of miRNAs and failed to evaluate each miRNA for its correlation with survival independently, it wouldn’t be selected for being less representative and relevant to our research. Distinct from earlier meta-analyses, the present work paid substantial attention to the details of study design and data reporting in quality assessment. A study would be presumed to exhibit compromised generalizability and then rejected if it failed to specify the cancer stage of its participants or it merely involved
patients of one certain stage. Moreover, in order to guarantee the homogeneity of enrolled studies and consequently the reliability of pooled result two studies [42,53] that measured miR-21 expression continuously were excluded, but both studies reported that high levels of miR-21 was related with poor survival in cancer, which was consistent with our finding in the current meta-analysis. Of importance, the included OS and DFS studies were both put to stratified analysis according to the sources of mir-21. To our knowledge, our study was unique in adopting that subgroup analysis and supplied initial quantitative evidence about the prognostic value of circulating and tissue mir-21 respectively. Besides, in the presence of heterogeneity among DFS studies, we performed further sensitivity and subgroup analysis, which was obviously absent from earlier relevant meta-analyses, to track down the origin of heterogeneity. By that means we fulfilled a comprehensive exploration and arrived at objective and unbiased conclusions.

Nonetheless the present meta-analysis study does have several limitations. To start with, substantial heterogeneity existed among the DFS studies, which was mainly caused by a relative paucity of studies evaluating DFS as an outcome. The divergence of incorporated studies was also probably ascribed to the difference in the demographics of participants, site of cancer, duration of follow-up, type of specimen, method of assay and cut-off value of mir-21 level. In the subgroup analysis of DFS studies, heterogeneity was eliminated in the non-Asian studies ($I^2 = 0.0\%$), and it was discovered that increased mir-21 expression was correlated with shortened DFS in non-Asian cancer patients. In order to minimize the confounding influence of heterogeneity, random effect model was used in the pooling of effect size. Moreover, in the final conclusion of our analysis we failed to specify the definition of mir-21 over-expression due to the inconsistency in the cut-off values of mir-21 level among the included studies. Furthermore, the analysis results of the NSCLC studies should be interpreted with caution because of a relatively small sample size (405 participants). Additionally, in the analysis of DFS studies the research by OTA et al, which fell into the circulating mir-21 subgroup, measured mir-21 level in bone marrow and the derived result might not appropriately apply to circulating mir-21. Last but not least, publication bias was detected in the DFS studies, indicating that studies with positive findings were more likely to be published over-estimate of the pooled HR.

Together with previous findings, our study has provided convincing evidence supporting mir-21 as a promising prognostic biomarker for cancer. Yet several considerations have to be delivered over its clinical application. First, priority must be given to the standardization of mir-21 assay procedure, including the methods of assay (qRT-PCR, ISH, IHC etc.), selection of internal reference RNA and most importantly, the cut-off value of mir-21 expression level. To a large extent, the divergence of contemporary findings about the prognostic value of mir-21 could be accredited to methodological inconsistency. The approach to setting cut-off value of mir-21 expression varied among different studies, which is obviously the principal concern needed to be resolved prior to its clinical application. Determination of global patterns of mir-21 expression will significantly prompt achievement of final consensus. In addition, in our study circulating mir-21 only displayed modest ability to discriminate outcomes, though it has been actively proposed as a non-invasive indicator of prognosis for numerous malignancies in latest years. Dispute existed in abundance concerning the authentic efficacy of cell-free mir-21 in differentiating outcomes. According to Chen et al [54], extracellular mir-21 probably originated from normal and/or tumor-lysed cells in the body fluids, which definitely created interference to the results obtained. Further studies are necessary to address that discrepancy and clarify the prognostic value of circulating mir-21.

In summary, our study has demonstrated that over-expression of mir-21 was effectively predictive of worse prognosis in various carcinomas. Increased mir-21 level in cancerous tissues was associated with reduced OS and DFS while elevated circulating mir-21 was only indicative of poor OS. In future more clinical studies are warranted to confirm the prognostic role of mir-21 before its practical implementation in management of cancer.

Supporting Information

Figure S1 Sensitivity analyses of studies concerning mir-21 and DFS. (TIF)

Table S1 Summary of the characteristics of enrolled studies. (DOCX)

Checklist S1 PRISMA 2009 Checklist. (DOC)

Author Contributions

Performed the experiments: WZ. Analyzed the data: BX WZ. Contributed reagents/materials/analysis tools: WZ. Wrote the paper: BX WZ. Study design: BX.

References

1. Croce CM, Calin GA (2005) miRNAs, cancer and stem cell division. Cell 122: 6–7.
2. Fabian MR, Sonenberg N (2012) The mechanics of miRNA-mediated gene silencing: A look under the hood of miRISC. Nat Struct Mol Biol 19: 596–599.
3. Ahmad A, Ali AS, Ali S, Wang Z, Kong D, et al (2011) MicroRNAs: Targets of Interest in Breast Cancer Research. In: Mulligan JA, editor. MicroRNA: Expression, Detection and Therapeutic Strategies. Hauppauge: Nova Science Publishers. 59–78.
4. Lee RG, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75: 843–854.
5. Garzon R, Fabrizi M, Gimmiene A, Calin GA, Croce CM (2006) MicroRNA expression and function in cancer. Trends Mol Med 12: 580–587.
6. Barh D, Malhotra R, Ravi B, Sindurrana P (2010) MicroRNA let-7: An emerging next-generation cancer therapeutic. Curr. Oncol 17: 70–80.
7. Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15–20.
8. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 205–217.
16. Chan JA, Krichevsky AM, Kosik KS (2005) MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65: 6029–6033.

17. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, et al (2008) Programmed cell death 4 (PDCD4) is an important functional target of the microRNA-21 in breast cancer cells. J Biol Chem 283: 1026–1033.

18. Frezzetti D, De Menna M, Zeppoli P, Guerra C, Ferraro A, et al (2011) Upregulation of miR-21 by Ras in vivo and its role in tumor growth. Oncogene 30: 275–286.

19. Medina PP, Noldie M, Slack FJ (2010) OncorniR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 467: 86–90.

20. Yan LX, Wu QN, Zhang Y, Li YY, Liao DZ, et al (2011) Knockdown of miR-21 in human breast cancer cells lines inhibits proliferation, in vitro migration and in vivo tumor growth. Breast Cancer Res 13: R2.

21. Krichevsky AM, Gabriely G (2009) miR-21: a small multi-faceted RNA. J Cell Biol Res 18: 997–1006.

22. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103: 2257–2261.

23. Wang B, Zhang Q (2012) The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J Cancer Res Clin Oncol 138: 1659–1666.

24. Lee EJ, Guey V, Jiang J, Nuovo GJ, Lerner MR, et al (2007) Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 120: 1046–1054.

25. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, et al (2008) MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299: 425–36.

26. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, et al (2008) MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 14: 2348–2360.

27. Wang JH, Voornstein J, Giovannetti E, Steinberg SM, Leon LG, et al (2012) Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS ONE 5: e10630. Available at: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0010630. Accessed at 19 December 2013.

28. Asaga S, Kuo C, Arangi T, Terpenning M, Guha A, et al (2011) Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem 57: 84–91.

29. Liu R (2012) Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem 58: 610–618.

30. Gao W, Lu X, Liu L, Xu J, Feng D, et al (2012) MiRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non small cell lung cancer. Cancer Biol Ther 13: 330–340.

31. Shen J (2011) Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer 11: 1245–1253.

32. Lawrie CH, Soneji S, Marafioti T, Cooper CD, Palazzo S, et al (2007) MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer 121: 1156–1161.

33. Chidlov G, Fazzaari M, Kang G, Kawachi N, Brandwein-Gensler M, et al (2009) Low-level expression of microRNAs let-7d and miR-203 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol 174: 736–745.

34. Henghean HM, Miller N, Kelly R, Newell J, Kerin MJ (2010) Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting non-invasive and early stage disease. Oncologist 15: 673–682.

35. Qian B, Katsaros D, Lu L, Preti M, Durando A, et al (2009) High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res Treat 117: 131–140.

36. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283: 2008–2012.

37. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2335–2346.

38. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634.

39. Zhao Y, Schetter AJ, Yang GP, Nguyen G, Mathé EA, et al (2013) microRNA and inflammatory gene expression as prognostic marker for overall survival in esophageal squamous cell carcinoma. Int J Cancer 132: 2901–2909.

40. Markou A, Tsourouche EG, Kalamianis I, Fofiniou M, Georgoulis V, et al (2008) Prognostic value of mature microRNA-21 and microRNA-203 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem 54: 1696–1704.

41. Hirata K, Suzuki H, Isahada H, Matsumoto J, Tsugawa H, et al (2013) CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence. Br J Cancer 109: 379–386.

42. Nielsen BS, Jørgensen S, Fog JU, Soèles R, Christensen IJ, et al (2011) High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin Exp Metastasis 28: 27–38.

43. Jiang J, Lu X, Li J, Lu M, Jiang P, et al (2012) The status of microRNA-21 expression and its clinical significance in human cutaneous malignant melanoma. Acta Histochemica 114: 382–388.

44. Zhu S, Si ML, Wu H, Mo YY (2007) MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 282: 14329–14336.

45. Yang Y, Chaerkady R, Beer MA, Mendell JT, Pandey A (2009) Identification of miR-21 targets in breast cancer cells using a quantitative proteomic approach. Proteomics 9: 1374–1384.

46. Song B, Wang C, Liu J, Wang X, Lu L, et al (2010) MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J Exp Clin Cancer Res 29: 29.

47. Hatley ME, Patrick DM, Garcia MR, Richardson JA, Basel-Duby R, et al (2010) Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 18: 292–293.

48. Papagiannakopoulos T, Shapiro A, Kosik KS (2008) MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res 68: 8164–8172.

49. Wickramasinghe NS (2009) Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucleic Acids Res 37: 2584–2595.

50. Xia X, Yang B, Zhai X, Liu X, Shen K, et al (2013) Prognostic Role of microRNA-21 in Colorectal Cancer: a Meta-Analysis. PLoS ONE 8(11): e78126. doi:10.1371/journal.pone.0078126.

51. Fu X, Han Y, Wu Y, Zhu Y, Lu X, et al (2011) Prognostic role of microRNA-21 in various carcinomas: a systematic review and meta-analysis. Eur J Clin Investig 41: 1247–1253.

52. Wang Y, Gao X, Wei F, Zhang X, Yu J, et al (2013) Diagnostic and prognostic value of circulating miR-21 for cancer: A systematic review and meta-analysis. Gene 533: 389–397.

53. Xu Y, Xi QH, Ge WL, Zhang XQ (2013) Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer. Asian Pacific J Cancer Prev 14: 1057–1060.

54. Chen X, Ba Y, Ma L, Cai X, Yin Y, et al (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 995–1006.